Skip to main content
. 2022 Nov 28;19(11):853–866. doi: 10.11909/j.issn.1671-5411.2022.11.002

Figure 1.

Figure 1

7,8-DHF attenuated pressure overload-induced decompensate cardiac hypertrophy.

(A): Representative pictures of murine hearts in the sham, TAC surgery for 8 weeks, and 7,8-DHF (5 mg/kg/d)-treated groups; (B): HW, TL, and HW/TL in the sham, TAC, and 7,8-DHF-treated mice; (C) representative images of echocardiography; (D): EF, FS, LVPW,s, LVPW,d, LVV,s, LVV,d, LVID,s, and LVID,d in sham, TAC, and 7,8-DHF-treated mice. Data are expressed as mean ± SE, n = 6 in each group. *P < 0.05, **P < 0.01 vs. sham, #P < 0.05, ##P < 0.01 vs. TAC. EF: ejection fraction; HW: heart weight; FS: fractional shortening; LVID,s: end-systolic left ventricular internal diameter; LVID,d: end-diastolic left ventricular internal diameter; LVPW,s: left ventricular end-systolic posterior wall thickness; LVPW,d: left ventricular end-diastolic posterior wall thickness; LVV,d: end-diastolic left ventricular volume; LVV,s: end-systolic left ventricular volume; 7,8-DHF: 7,8-dihydroxyflavone; TAC: transverse aortic constriction; TL: tibia length.